International NASH Day
International NASH Day - held annually on June 12 - is dedicated to increasing awareness about non-alcoholic steatohepatitis, or NASH, among various populations: the general public, at-risk patients, the medical community, public health authorities, and the media.
Through locally-organized events around the world, advocates raise awareness and promote early intervention to treat fatty liver disease and its more advanced form, NASH, which affects more than 115 million people worldwide.
Advanced Advocacy Academy (A3)
A 2-day event connecting liver patients and family members with the information, skills, and opportunities that they need to effectively advocate for liver health.
A3 2019 will take place on November 1-2, 2019 at GLI Headquarters in Washington, DC. This year’s program will offer liver patients, caregivers, and professionals the opportunity to learn from experts in the fields of drug development, state and federal legislation, media and communications, and liver health and disease. If you or someone you know is interested in attending, apply online, or email email@example.com with any questions.
The purpose of the NASH Council is to shine a spotlight and coalesce an expanded set of stakeholders, in addition to hepatology, around the urgency of developing mechanisms for quantifying and addressing the silent epidemic of fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in the U.S. and abroad. Current estimates are that as many as 1 in 4 people already have NAFLD or NASH yet these conditions are underrecognized, underdiagnosed, and undertreated.
Liver Cancers Council
Global Liver Institute’s Liver Cancers Council has been established to elevate the recognition of liver cancer’s prevalence and impact; promote regular screening and early diagnosis; increase the amount and quality of liver cancer-specific education, navigation, and policy; and to train liver cancer advocates to advance patient-centered research, care, support, and policy.
Beyond the Biopsy
The Beyond the Biopsy awareness campaign is dedicated to accelerating the acceptance and adoption of noninvasive technologies as an alternative to biopsy.
Though it has been long considered the gold standard for diagnosing and staging liver disease such as Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH), liver biopsy is an invasive, potentially inaccurate, and risky procedure.